9.14 (-%)
As of Nov 01, 2024
Source:
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate,pegozafermin (previously BIO89-100),a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Country | United States |
Headquarters | san francisco, california |
Phone Number | (415) 432-9270 |
Industry | manufacturing |
CEO | Rohan Palekar |
Website | www.89bio.com. |